BioSpace News Archive

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present three abstracts at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.

SeaStar Medical Holding Corporation announces that management will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18 at 9:30 a.m. Eastern time.

Provectus Biopharmaceuticals, Inc. were presented at the annual meeting of the American Association for Cancer Research (“AACR”), held April 5-10, 2024 in San Diego, California.

Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, today announces that top line results of its certification study REMOVE assessing the Company’s medical device for the removal of tumor cells from intraoperative blood during high-blood loss surgeries will be presented at the NATA24 Annual Symposium.

QT Imaging Holdings, Inc. a medical device company engaged in research, development, and commercialization of innovative body imaging systems, together with our strategic business and distribution partner are proud to announce their partnership with the Center of New Medicine in Irvine, California.

Baxter International Inc. announced the continued expansion of its Pharmaceuticals portfolio with five injectable product launches in the U.S. “These launches demonstrate Baxter’s focus on differentiated products that address unmet patient needs in key therapeutic areas, including anti-infective and anti-hypotensive medications,” said Alok Sonig, executive vice president and group president, Pharmaceuticals, at Baxter.

Crown Bioscience today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.

MEI Pharma, Inc. today reported that the Company’s Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation for Phase 1 study.

Researchers at the newly-formed Optimal Aging Institute at NYU Langone Health have been awarded $31 million by the National Institutes of Health for a diverse, ten university cohort to study how vascular risk factors contribute to dementia and other age-related disorders in those over the age of 85, building upon existing research.

The Management Board and Supervisory Board of MorphoSys AG issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG, recommending that shareholders accept the offer and tender their MorphoSys shares.